Bihua Chen - Dec 13, 2022 Form 4/A - Amendment Insider Report for Erasca, Inc. (ERAS)

Role
Director
Signature
/s/ Bihua Chen
Stock symbol
ERAS
Transactions as of
Dec 13, 2022
Transactions value $
$1,999,998
Form type
4/A - Amendment
Date filed
12/21/2022, 03:33 PM
Date Of Original Report
Dec 20, 2022
Previous filing
Jun 24, 2022
Next filing
Dec 20, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ERAS Common Stock Purchase $2M +308K +2.93% $6.50 10.8M Dec 13, 2022 See Footnotes F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ERAS Stock Option (right to buy) 167K Dec 13, 2022 Common Stock 167K $5.81 Direct F4, F5
holding ERAS Stock Option (right to buy) 40K Dec 13, 2022 Common Stock 40K $5.35 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Ms. Chen disclaims beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Ms. Chen is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
F2 Represents (i) 2,986,402 shares of Common Stock held by the Master Fund, (ii) 7,716,444 shares of Common Stock held by Fund II, and (iii) 110,400 shares of Common Stock held by the Account.
F3 Shares reported herein as purchased on December 9, 2022 were purchased by the Master Fund.
F4 Stock option grant for 166,666 shares, 41,667 shares of which become exercisable on 3/16/2022 and 124,999 shares of which become exercisable thereafter in equal monthly installments through 3/16/2025.
F5 Stock options granted to Bihua Chen, in her capacity as a director of the Issuer.

Remarks:

This amendment is being filed to clarify that the Form 4 filed by the Reporting Persons on December 20, 2022 was signed on such date and to correct a typographical error in the Date of Earliest Transaction reported in such Form 4.